- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Zydus Lifesciences gets USFDA nod to market colestipol hydrochloride tablets
The approval by the US Food and Drug Administration is for colestipol hydrochloride of 1 mg strength, the company said in a regulatory filing.
New Delhi: Zydus Lifesciences Ltd on Monday said it has received the final approval from the US health regulator to market its generic version of colestipol hydrochloride tablets, which is used to lower cholesterol. The approval by the US Food and Drug Administration is for colestipol hydrochloride of 1 mg strength, the company said in a regulatory filing.Colestipol hydrochloride tablets...
New Delhi: Zydus Lifesciences Ltd on Monday said it has received the final approval from the US health regulator to market its generic version of colestipol hydrochloride tablets, which is used to lower cholesterol. The approval by the US Food and Drug Administration is for colestipol hydrochloride of 1 mg strength, the company said in a regulatory filing.
Zydus' global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.
Read Also -Zydus gets USFDA nod for diabetes drug Dapagliflozin
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.